突破性感染后加强针对SARS-CoV-2奥密克戎BA.5.2.48和XBB.1亚变体的中和作用较低
该横断面研究纳入64例突破性感染患者,采集512份血清样本,按疫苗接种剂次分为未接种后一剂组12例、两剂组15例、三剂组37例,用聚焦减少中和试验检测针对SARS-CoV-2及其变异株的中和抗体。结果显示,无论接种两剂还是三剂疫苗,针对奥密克戎亚变体的中和抗体几何平均滴度(GMT 66.8和56.1)均显著低于原始株;突破性感染血清诱导广谱中和,但奥密克戎XBB.1.16表现出高免疫逃逸潜力。
要点
- 突破性感染血清对奥密克戎亚变体的中和抗体GMT(66.8和56.1)显著低于原始株,两剂和三剂疫苗均如此。
- 突破性感染血清诱导广谱中和,但奥密克戎XBB.1.16表现出高免疫逃逸潜力。
- 研究为横断面设计,纳入64例突破性感染患者,共检测512份血清样本。
核心结论
- 突破性感染血清诱导广谱中和,但奥密克戎XBB.1.16表现出高免疫逃逸潜力。
- 无论接种两剂还是三剂疫苗,针对奥密克戎亚变体的中和抗体GMT(66.8和56.1)均显著低于原始株。
研究设计与样本
- 横断面研究,招募64例突破性感染患者。
- 共获取512份血清样本,来自未接种后接种一剂疫苗者12例、接种两剂疫苗者15例、接种三剂疫苗者37例。
- 采用聚焦减少中和试验检测针对SARS-CoV-2及其变异株的中和抗体。
主要发现
- 针对奥密克戎亚变体的中和抗体GMT为66.8和56.1,显著低于原始株,无论接种两剂还是三剂疫苗。
- 突破性感染血清诱导广谱中和,但奥密克戎XBB.1.16表现出高免疫逃逸潜力。
关键数值与推荐
- 中和抗体GMT:奥密克戎亚变体为66.8和56.1,显著低于原始株,无论两剂或三剂疫苗接种。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To assess the levels of and neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its mutants in serum samples from patients with breakthrough infection. Sixty-four patients with breakthrough infections were recruited for this cross-sectional study. All samples were used to neutralizing antibodies (nAbs) against SARS-CoV-2 and its mutants using a focused reduction neutralization assay. A total of 512 serum samples were obtained from unvaccinated patients who received one dose of vaccine (n = 12), received two doses of vaccine (n = 15), and received three doses of vaccine (n = 37). The geometric mean titer (GMT) of neutralizing antibodies against the Omicron subvariant was significantly lower (GMT 66.8 and 56.1) compared to the original strain, regardless of whether two or three doses of vaccine were administered. This result highlights that sera from breakthrough infections induce broad neutralization, but Omicron XBB.1.16 exhibits high immune evasion potential.
引用
- Li J, Gong L, Li J, et al. Low neutralization of SARS-CoV-2 Omicron BA.5.2.48 and XBB.1 sub-variants in response to breakthrough infection by booster. Vaccine. 2024. PMID: 38714449. doi:10.1016/j.vaccine.2024.04.093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。